Business Context and Reporting Period
This Form 6-K filing by MDxHealth SA covers the month of December 2023, with the report dated December 19, 2023. The primary purpose of this filing is to disclose the completion of the de-listing of the Company's ordinary shares from Euronext Brussels and the corresponding amendments to its Articles of Association.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status changes rather than financial performance data.
Material Changes
- De-listing: The Company's ordinary shares ceased trading on Euronext Brussels on December 15, 2023, which was the last trading day.
- Articles of Association: On December 15, 2023, the Company amended its Articles of Association to revise provisions related to the de-listing.
- Shareholder Approval: These actions were approved by shareholders at an extraordinary general meeting held on November 3, 2023.
Outlook, Risks, and Management Commentary
The filing references a press release issued on December 18, 2023 (attached as Exhibit 99.1), but the text of the press release is not included in the provided content. Consequently, specific management commentary, future guidance, or detailed risk factors regarding the post-de-listing strategy are not available in this summary. The filing explicitly states that the attached exhibits are furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the final status of the Company's shares following the December 15, 2023 de-listing from Euronext Brussels.
- Review the attached Exhibit 3.1 to understand the specific amendments made to the Articles of Association.
- Obtain the full text of the December 18, 2023 press release (Exhibit 99.1) for details on the Company's future capital structure or strategic direction.
- Confirm the current trading venue or private status of the Company's shares post-de-listing.